Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
How do you treat front line de novo HER2 positive metastatic breast cancer with brain metastases?
Related Questions
In what situations would you consider doublet chemotherapy in treatment of a premenopausal de novo metastatic TNBC?
Do you routinely check echocardiograms on all patients who are starting TDM1?
Do you use elacestrant for all patients with metastatic ER+, HER2-, ESR1 mutated breast cancer regardless of duration of response to prior ET+CDK4/6i?
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
In a patient with hormone-positive early breast cancer who experienced a myocardial infarction (MI) while on aromatase inhibitors (AI), should tamoxifen be considered as an alternative treatment?
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
Would you consider using tucatinib in a patient with de-novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
What is your recommended treatment sequencing strategy in patients with HER2+ breast cancer and leptomeningeal carcinomatosis?
What are your top takeaways in Breast Cancer from ESMO 2024?
